Slow cardiac myosin regulatory light chain 2 (MYL2) was down-expressed in chronic heart failure patients.
BACKGROUND
Genetic studies have shown that many slow cardiac myosin regulatory light chain 2 (MYL2) gene mutations can cause hypertrophic cardiomyopathy, which is one of the most common causes of heart failure (HF). But until now there has been no pathological or histological evidence that MYL2 may be associated with HF development. Recent microarray studies indicated that myosin heavy chain expression changed in the pathological process of HF. Because MYL2 is a regulatory component of myosin heavy polypeptide, the role of MYL2 protein in HF needs to be studied.


OBJECTIVE
The level of expression of MYL2 may change in the heart tissue of patients with chronic HF.


METHODS
We collected 28 human right auricle samples, 16 from chronic HF patients and 12 from healthy control subjects. Immunohistochemistry was carried out to observe the tissue-expression pattern of the MYL2 protein and Western blot methods were performed to quantify the relative MYL2 expression level.


RESULTS
In chronic HF patients, the MYL2 protein level decreased significantly compared with normal controls (t test P < 0.05). Among the 16 HF patients, MYL2 expression in the severe HF group (New York Heart Association [NYHA] class III or IV) was even lower than that of the moderate HF group (NYHA class II) (t test P < 0.05).


CONCLUSIONS
MYL2 was down-expressed in HF tissues, and our findings suggested that MYL2 may play a role in the development and progression of chronic HF.
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
Yuanhong
Y
Li
Gang
G
Wu
Qizhu
Q
Tang
Congxin
C
Huang
Hong
H
Jiang
Lisong
L
Shi
Xin
X
Tu
Jinqi
J
Huang
Xiaoqing
X
Zhu
Hongli
H
Wang
D000293:Adolescent; D000328:Adult; D000368:Aged; D015153:Blotting, Western; D016022:Case-Control Studies; D002908:Chronic Disease; D015536:Down-Regulation; D005260:Female; D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000737:chemistry*; D018994:Myosin Light Chains / Q000032:analysis*; D012720:Severity of Illness Index
C466107:MRLC2 protein, human; D018994:Myosin Light Chains
Circulation. 2003 May 6;107(17):2227-32
12707239
J Cell Sci. 2005 Aug 15;118(Pt 16):3675-83
16076902
N Engl J Med. 2008 May 1;358(18):1899-908
18403758
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):10973-8
15256600
J Mol Med (Berl). 1998 Mar;76(3-4):208-14
9535554
Circ J. 2008;72 Suppl A:A13-6
18772527
Pacing Clin Electrophysiol. 2009 Jul;32 Suppl 2:S23-31
19602159
Eur J Hum Genet. 2002 Nov;10(11):741-8
12404107
Eur Heart J. 2008 Oct;29(19):2388-442
18799522
Lancet. 2005 May 28-Jun 3;365(9474):1877-89
15924986
Eur J Hum Genet. 2009 Oct;17(10):1241-9
19293840
Circ J. 2009 Sep;73(9):1568-76
19638707
J Med Genet. 2005 Oct;42(10):e59
16199542
Int J Biochem Cell Biol. 2008;40(9):1643-8
18514564
J Am Coll Cardiol. 2006 Oct 17;48(8):1610-7
17045896
Hum Mutat. 2008 Jun;29(6):879-85
18409188
Circ Heart Fail. 2009 May;2(3):253-61
19808347
J Appl Physiol (1985). 2002 Apr;92(4):1661-70
11896035
J Biol Chem. 2001 Mar 9;276(10):7086-92
11102452
Biochem Biophys Res Commun. 2010 Feb 26;393(1):55-60
20100464
Cell Mol Biol Res. 1993;39(1):13-26
8287067
JAMA. 2002 Mar 13;287(10):1308-20
11886323